Breast cancer is the most frequent tumor among women. In Spain, more than 22,000 new cases are diagnosed annually. The positive part is that the cancer mortality rate has decreased in the last years.
Breast cancer is a malignant tumor that it originates from the mammary gland tissue and it has the capacity to invade the surrounding healthy tissues and spread into other organs.
According CRIS CONTRA EL CANCER foundation, from a clinical-pathological point of view, we can classify breast cancer in three groups:
Tumors with hormone receptor expression.
We find the hormone receptor in the membrane of the cell and this hormone receptor transmit signals inside the cell.
Tumors overexpressing HER2 protein kinase transmembrane.
This protein stimulates the growth of the cell and it can do that these cells don’t stop of multiplying. This kind of tumors are characterized by present an aggressive clinical course and unpleasant prognosis. The 25% of breast cancer tumors are of this kind.
Tumors that lack high expression of these markers and are classified as triple-negative tumors.
These tumors not responding to the treatments, they are more aggressive and the patients can suffer relapses. This kind of tumors are 15% of all breast cancer tumors and only the chemotherapy slowers their growth speed.
CRIS CONTRA EL CÁNCER is an independent organization dedicated to the promotion and development of research to eliminate cancer. This research foundation wants to deepen in the knowledge of the mechanisms responsible for the resistance to anti-HER2 therapies and then propose alternative treatments and develop new medicines to improve the prognostic and the curation rate of the breast cancer patients whose tumors are tough to current anti-HER2 medicines.
The research team of Dr. Alberto Ocaña and Dr. Anastasio Pandiella are responsible to execute this research. With the aim to help to develop this research and develop new medicines to improve the prognostic and the curation rate our e-commerce with a cause Pc Componentes will offer to his clients the option to make a donation to this project.
Thanks to the solidarity of the Pc Componentes customers this research team will make a detailed analysis of the mechanisms responsible for the resistance to anti-HER2 therapies, they will generate in vitro and “in vivo” models of resistance to anti-HER2 therapies and they will execute all of them with one aim: identify the causes associated to resistance of certain treatments and develop new drugs to improve the prognosis and cure rate.
A decade ago, if one doctor diagnosed a HER2 breast cancer to a woman it meant that she could die in less than 20 months. Thanks to the researches that cute this kind of cancer, the life of women who have this cancer has been extended and, according to ESMO (European Society of Medical Oncology) if the cancer hasn’t been extended to other organs, this kind of tumor will be able to be cured in 90% of cases.
We want to give our support to the research to fight for breast cancer and we want to encourage that you do the same.
The Worldcoo team.